Skip to main content

Table 1 Baseline characteristics of patients with normal mPAP, BoPAP and PAH

From: Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study

  Patient groups (N =244) P-value
Variable Normal mPAP (N =148) BoPAP (N =36) PAH (N =60) BoPAP versus normal mPAP PAH versus BoPAP
Demographic and clinical parameters  
Age, years, Na 148 36 59   
  Mean ± SD 54.3 ± 12.0 58.4 ± 9.5 61.6 ± 9.7
  Median, Q1 to Q3 55.0, 46.0 to 63.5 58.5, 52.5 to 63.5 62.0, 56.0 to 68.0
  Minimum, maximum 26.0, 78.0 43.0, 80.0 33.0, 80.0
Gender, n 148 36 60   
  Male, n (%) 18 (12.2) 6 (16.7) 12 (20.0)
  Female, n (%) 130 (87.8) 30 (83.3) 48 (80.0)
WHO FC, N 139 34 60   <0.05
  I/II, n (%) 127 (91.4) 28 (82.4) 37 (61.7)
  III/IV, n (%) 12 (8.6) 6 (17.6) 23 (38.3)
6-minute walk distance, N 108 27 48   
  Mean ± SD 422.4 ± 110.4 397.4 ± 102.3 391.4 ± 109.8
  Median, Q1 to Q3 432.5, 364.5 to 502.0 414.5, 341.0 to 472.0 395.0, 318.0 to 460.5
SSc disease duration (years), N 147 36 60   
  Mean ± SD 11.0 ± 8.0 10.0 ± 5.0 14.0 ± 12.0
  Median, Q1 to Q3 8.0, 5.0 to 13.0 9.0, 6.0 to 15.0 11.0, 6.0 to 16.0
SSc subtype, N 146 36 59   
  Limited, n (%) 90 (61.6) 20 (55.6) 44 (74.6)
  Diffuse, n (%) 45 (30.8) 13 (36.1) 10 (16.9)
  Overlap/mixed CTD, n (%) 11 (7.5) 3 (8.3) 5 (8.5)
Presence of peripheral edema, n/N (%) 8/147 (5.4) 7/36 (19.4) 11/60 (18.3) <0.01  
Presence of telangiectasias, n/N (%) 108/148 (73.0) 22/36 (61.1) 52/60 (86.7)   <0.005
FVC % predicted, N 148 36 60   
  Mean ± SD 92.5 ± 17.6 88.7 ± 14.5 92.0 ± 19.7
  Median, Q1-Q3 91.9, 79.9 to 102.7 87.1, 80.0 to 96.5 89.5, 77.2 to 102.5
FVC % predicted /DLCO % predicted, N 148 36 60   <0.01
  Mean ± SD 1.9 ± 0.4 1.9 ± 0.4 2.3 ± 0.7
  Median, Q1 to Q3 1.8, 1.5 to 2.1 2.0, 1.5 to 2.2 2.2, 1.8 to 2.5
TLC % predicted, N 127 28 54 <0.05  
  Mean ± SD 92.8 ± 21.9 84.8 ± 14.4 88.1 ± 21.6  
  Median, Q1 to Q3 92.5, 80.0 to 106.0 83.0, 74.0 to 95.0 87.3, 78.0 to 100.3  
Serum laboratory tests  
Presence of anti-centromere antibodies      <0.05
n/N (%) 49/141 (34.8) 10/34 (29.4) 30/56 (53.6)
Log10 NT-proBNP (pg/ml), N 141 34 56 <0.05  
  Mean ± SD 2.0 ± 0.5 2.2 ± 0.5 2.4 ± 0.5
  Median, Q1 to Q3 2.1, 1.7 to 2.3 2.2, 1.9 to 2.5 2.3, 2.0 to 2.8
Serum urate, mg/100 ml, N 141 34 56   <0.01
  Mean ± SD 4.7 ± 1.4 4.7 ± 1.3 5.6 ± 1.4
  Median, Q1 to Q3 4.4, 3.7 to 5.3 4.5, 3.7 to 5.4 5.6, 4.6 to 6.5
Log10 estimated GFR 141 34 55   
1.9 ± 0.1 1.9 ± 0.1 1.9 ± 0.1
1.9, 1.9 to 2.0 1.9, 1.8 to 2.0 1.9, 1.8 to 2.0
Echocardiography  
Left atrium diameter, mm, N 148 36 60 <0.001  
  Mean ± SD 30.2 ± 5.1 33.9 ± 3.6 31.8 ± 5.4
  Median, Q1 to Q3 31.0, 27.8 to 34.0 33.5, 31.0 to 37.0 32.0, 30.0 to 36.0
Right atrium area, cm2, N 142 33 58   <0.05
  Mean ± SD 12.8 ± 4.7 14.7 ± 5.9 16.8 ± 5.8
  Median, Q1 to Q3 12.0, 10.0 to 14.3 12.4, 10.5 to 18.0 15.8, 13.4 to 20.0
TAPSE (mm), N 138 33 53   
  Mean ± SD 23.2 ± 4.3 23.8 ± 5.1 21.1 ± 4.3
  Median, Q1 to Q3 23.7, 20.4 to 26.0 23.0, 20.0 to 27.0 20.8, 19.0 to 23.0
TR velocity (m/s), N 140 35 58 <0.001 <0.05
  Mean ± SD 2.3 ± 0.4 2.7 ± 0.3 3.0 ± 0.7
  Median, Q1 to Q3 2.3, 2.2 to 2.6 2.7, 2.5 to 2.9 2.9, 2.5 to 3.5
Electrocardiography  
Presence of right axis deviation, n/N (%) 2/138 (1.4) 1/30 (3.3) 8/58 (13.8)   
Right heart catheterization  
PAWP, mmHg, N 148 36 60 <0.001  
  Mean ± SD 7.7 ± 3.3 10.8 ± 3.0 9.9 ± 3.3
  Median, Q1 to Q3 8.0, 5.0 to 10.0 11.0, 9.0 to 13.0 10.5, 7.5 to 12.5
TPG, mmHg, N 148 36 60 <0.001 <0.001
  Mean ± SD 7.9 ± 2.7 11.6 ± 2.8 22.3 ± 9.7
  Median, Q1 to Q3 7.0, 6.0 to 10.0 11.0, 10.0 to 13.0 20.0, 15.0 to 28.0
DWG, mmHg, N 148 36 60   <0.001
  Mean ± SD 1.8 ± 2.7 3.0 ± 5.4 10.7 ± 8.1
  Median, Q1 to Q3 1.0, 0.0 to 3.0 2.0, 0.5 to 5.0 8.0, 5.0 to 17.0
PVR, dyn.sec/cm5, N 148 36 60 <0.001 <0.001
  Mean ± SD 128.0 ± 50.8 179.8 ± 58.7 375.8 ± 217.0
  Median, Q1 to Q3 121.5, 91.3 to 153.9 170.3, 147.8 to 187.8 295.5, 236.0 to 419.1
  1. aN for each variable represents the number of patients with available data. Statistical tests were Wilcoxon rank-sum for continuous data and chi-square/Fisher’s exact for categorical data. ‘These variables were analysed for completeness, but it should be borne in mind that they are part of the definition of the analysis groups. BoPAP, borderline pulmonary arterial pressure; CTD, connective tissue disease; DLCO, diffusing capacity of carbon monoxide; DWG, diastolic wedge gradient; FVC, forced vital capacity; GFR, glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; Q, quartile; SSc, systemic sclerosis; TAPSE, tricuspid annular plane systolic excursion; TLC, total lung capacity; TPG, transpulmonary gradient; TR, tricuspid regurgitation; WHO FC, World Health Organization functional class.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us